The pharmaceutical company Double Bond Pharma has entered into a loan agreement with existing shareholder Investentia for up to SEK 5 million, with the possibility of conversion into the Company's B shares. The loan is to be disbursed monthly until December 2026, and also gives the lender the right, during the period 1 December 2026 to 31 January 2027, to call for a new share issue corresponding to any unused portion of the loan facility. This is stated in a press release."We warmly welcome this investment and, on behalf of the Board, would like to extend our deep thanks to Investentia for their long-term support. The investment not only strengthens our ability to execute the Company's strategy and continue our development journey, but it also reinforces our position at the negotiating table. This is crucial for us to secure optimal and favorable agreements with potential partners regarding our key project SI053," says CEO Igor Lokot.